Abstract
There is no known biomarker for follow-up of patients with sarcoidosis. Visfatin is a proinflammatory adipokine which has been studied for several inflammatory diseases such as diabetes mellitus, obesity and metabolic syndrome. Our aim was to evaluate visfatin together with inflammatory biomarkers like serum ACE, sedimentation and CRP.
59 patients with sarcoidosis were included in our study. Serum concentrations of visfatin were analyzed by ELISA. Patients were divided into those with and without parenchymal involvement. Serum ACE levels and ESR were significantly higher in patients with pulmonary involvement. There was no association between CRP levels, serum visfatin concentration and parenchymal involvement.
We think visfatin is not a useful biomarker for diagnosing and monitoring sarcoidosis.
- Copyright ©the authors 2017